# US 2016/0250198 A1 · Pirfenidone Treatment for Patients with Atypical Liver Function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250198 A1
- Document ID: US20160250198A1
- Status: Published application
- Kind: A1
- Application number: 15/148,792
- Filed: 2016-05-06
- Published: 2016-09-01
- Earliest claimed: 2008-11-10
- Assignees: Intermune, Inc.
- Applicants: Intermune, Inc.
- Inventors: Williamson Z. Bradford; Javier Szwarcberg
- Web page: https://patentgrep.com/patent/US20160250198A1

## CPC

- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/16: Central respiratory analeptics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/08: for leprosy
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/576: for hepatitis
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.

## Claims

### Claim 1

A method of administering pirfenidone to treat a patient who would benefit from pirfenidone administration, optionally a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, comprising (a) administering to said patient pirfenidone at doses of at least 1600 mg/day or 1602 mg/day.

### Claim 2 (depends on 1)

A method of claim 1 comprising (a) administering to said patient pirfenidone at doses of 2400 mg/day or 2403 mg/day.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2 further comprising, prior to step (a), administering to said patient pirfenidone at doses lower than 2400 mg/day for a time period.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3 wherein prior to step (a) pirfenidone is discontinued until biomarkers of liver function are within normal limits.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any of claims 1-4 further comprising, prior to step (a), administering about 1600 mg/day or 1602 mg/day pirfenidone for a period of time, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any of claims 1-5 further comprising, prior to step (a), administering about 800 mg/day or 801 mg/day pirfenidone for a period of time, optionally about one week, or until biomarkers of liver function are within normal limits, followed by administering about 1600 mg/day or 1602 mg/day pirfenidone for a period of time, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any of claims 1-6 further comprising, prior to step (a), discontinuing pirfenidone for a period of time, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1-7, wherein the pirfenidone is administered three times per day with food.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any of claims 1-8, wherein said one or more biomarkers of liver function is selected from the group consisting of alanine transaminase, aspartate transaminase, and bilirubin.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9 further comprising the step of measuring one or more biomarkers of liver function.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein said one or more biomarkers of liver function are alanine transaminase and aspartate transaminase.

### Claim 12

Pirfenidone for use in treating a patient who would benefit from pirfenidone administration, optionally a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of 2400 mg/day or 2403 mg/day.

### Claim 13 (depends on 11)

Pirfenidone for use in treating a patient according to claim 11, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 2400 mg/day for a time period.

### Claim 14 (depends on 11, 12)

Pirfenidone for use in treating a patient according to claim 11 or 12, wherein, prior to step (a), pirfenidone administration to the patient is discontinued for a time period, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 15 (depends on 11, 12, 13)

Pirfenidone for use in treating a patient according to any of claims 11-13, wherein, prior to step (a), about 1600 mg/day or 1602 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 16 (depends on 11, 12, 13, 14)

Pirfenidone for use in treating a patient according to any of claims 11-14, wherein, prior to step (a), about 800 mg/day or 801 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits, and then about 1600 mg/day or 1602 mg/day pirfenidone is administered to the patient for a time period, optionally about one week or until biomarkers of liver function are within normal limits.

### Claim 17 (depends on 11, 12, 13, 14, 15)

Pirfenidone for use in treating a patient according to any of claims 11-15, wherein, prior to step (a), administration of pirfenidone is discontinued for a time period, optionally about one week, or until biomarkers of liver function are within normal limits, and then about 800 mg/day or 801 mg/day pirfenidone is administered for a time period, optionally about one week or until biomarkers of liver function are within normal limits, and then about 1600 mg/day or 1602 mg/day pirfenidone is administered for a time period, optionally about one week or until biomarkers of liver function are within normal limits.

### Claim 18 (depends on 11, 12, 13, 14, 15, 16)

Pirfenidone for use in treating a patient according to any of claims 11-16, wherein the pirfenidone is administered three times per day with food.

### Claim 19 (depends on 11, 12, 13, 14, 15, 16, 17)

Pirfenidone for use in treating a patient according to any of claims 11-17, wherein said one or more biomarkers of liver function is selected from the group consisting of alanine transaminase, aspartate transaminase, and bilirubin.

### Claim 20 (depends on 11, 12, 13, 14, 15, 16, 17, 18)

Pirfenidone for use in treating a patient according to any of claims 11-18 further comprising measuring one or more biomarkers of liver function.

### Claim 21 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

Pirfenidone for use in treating a patient according to any of claims 11-19, wherein said one or more biomarkers of liver function are alanine transaminase and aspartate transaminase.

### Claim 22

Use of pirfenidone in the manufacture of a medicament for treating a patient who would benefit from pirfenidone administration, optionally a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of 2400 mg/day or 2403 mg/day.

### Claim 23 (depends on 21)

Use according to claim 21, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 2400 mg/day for a time period.

### Claim 24 (depends on 21, 22)

Use according to claim 21 or 22, wherein, prior to step (a), pirfenidone administration to the patient is discontinued for a time period, optionally about one week or until biomarkers of liver function are within normal limits.

### Claim 25 (depends on 21, 22, 23)

Use according to any of claims 21-23, wherein, prior to step (a), about 1600 mg/day or 1602 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 26 (depends on 21, 22, 23, 24)

Use according to any of claims 21-24, wherein, prior to step (a), about 800 mg/day or 801 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits, and then about 1600 mg/day or 1602 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 27 (depends on 21, 22, 23, 24, 25)

Use according to any of claims 21-25, wherein, prior to step (a), administration of pirfenidone is discontinued for a time period, optionally about one week, or until biomarkers of liver function are within normal limits, and then about 800 mg/day or 801 mg/day pirfenidone is administered for a time period, optionally about one week or until biomarkers of liver function are within normal limits, and then about 1600 mg/day or 1602 mg/day pirfenidone is administered for a time period, optionally about one week or until biomarkers of liver function are within normal limits.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26)

Use according to any of claims 21-26, wherein the pirfenidone is administered three times per day with food.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27)

Use according to any of claims 21-27, wherein said one or more biomarkers of liver function is selected from the group consisting of alanine transaminase, aspartate transaminase, and bilirubin.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28)

Use according to any of claims 21-28 further comprising measuring one or more biomarkers of liver function during administration of pirfenidone.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

Use according to any of claims 21-29, wherein said one or more biomarkers of liver function are alanine transaminase and aspartate transaminase.

### Claim 32 (depends on 1)

The method according to claim 1, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 1600 mg/day for a time period.

### Claim 33 (depends on 1, 32)

The method according to claim 1 or 32, wherein, prior to step (a), pirfenidone administration to the patient is discontinued for a time period, optionally about one week or until biomarkers of liver function are within normal limits.

### Claim 34 (depends on 1, 32, 33)

The method according to any of claim 1 or 32-33, wherein, prior to step (a), about 800 mg/day or 801 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 35 (depends on 1, 32, 33, 34)

The method according to any of claim 1 or 32-34, wherein the pirfenidone is administered three times per day with food.

### Claim 36 (depends on 1, 32, 33, 34, 35)

The method according to any of claim 1 or 32-35, wherein said one or more biomarkers of liver function is selected from the group consisting of alanine transaminase, aspartate transaminase, and bilirubin.

### Claim 37 (depends on 1, 32, 33, 34, 35, 36)

The method according to any of claim 1 or 32-36 further comprising measuring one or more biomarkers of liver function during administration of pirfenidone.

### Claim 38 (depends on 1, 32, 33, 34, 35, 36, 37)

The method according to any of claim 1 or 32-37, wherein said one or more biomarkers of liver function are alanine transaminase and aspartate transaminase.

### Claim 39

Pirfenidone for use in treating a patient who would benefit from pirfenidone administration, optionally a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day or 1602 mg/day.

### Claim 40 (depends on 39)

Pirfenidone for use in treating a patient according to claim 39, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 1600 mg/day for a time period.

### Claim 41 (depends on 39, 40)

Pirfenidone for use in treating a patient according to claim 39 or 40, wherein, prior to step (a), pirfenidone administration to the patient is discontinued for a time period, optionally about one week or until biomarkers of liver function are within normal limits.

### Claim 42 (depends on 39, 40, 41)

Pirfenidone for use in treating a patient according to any of claims 39-41, wherein, prior to step (a), about 800 mg/day or 801 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 43 (depends on 39, 40, 41, 42)

Pirfenidone for use in treating a patient according to any of claims 39-42, wherein the pirfenidone is administered three times per day with food.

### Claim 44 (depends on 39, 40, 41, 42, 43)

Pirfenidone for use in treating a patient according to any of claims 39-43, wherein said one or more biomarkers of liver function is selected from the group consisting of alanine transaminase, aspartate transaminase, and bilirubin.

### Claim 45 (depends on 39, 40, 41, 42, 43, 44)

Pirfenidone for use in treating a patient according to any of claims 39-44 further comprising measuring one or more biomarkers of liver function during administration of pirfenidone.

### Claim 46 (depends on 39, 40, 41, 42, 43, 44, 45)

Pirfenidone for use in treating a patient according to any of claims 39-45, wherein said one or more biomarkers of liver function are alanine transaminase and aspartate transaminase.

### Claim 47

Use of pirfenidone in the manufacture of a medicament for treating a patient who would benefit from pirfenidone administration, optionally a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day or 1602 mg/day.

### Claim 48 (depends on 47)

The use according to claim 47, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 1600 mg/day for a time period.

### Claim 49 (depends on 47, 48)

The use according to claim 47 or 48, wherein, prior to step (a), pirfenidone administration to the patient is discontinued for a time period, optionally about one week or until biomarkers of liver function are within normal limits.

### Claim 50 (depends on 47, 48, 49)

The use according to any of claims 47-49, wherein, prior to step (a), about 800 mg/day or 801 mg/day pirfenidone is administered to the patient for a time period, optionally about one week, or until biomarkers of liver function are within normal limits.

### Claim 51 (depends on 47, 48, 49, 50)

The use according to any of claims 47-50, wherein the pirfenidone is administered three times per day with food.

### Claim 52 (depends on 47, 48, 49, 50, 51)

The use according to any of claims 47-51, wherein said one or more biomarkers of liver function is selected from the group consisting of alanine transaminase, aspartate transaminase, and bilirubin.

### Claim 53 (depends on 47, 48, 49, 50, 51, 52)

The use according to any of claims 47-52 further comprising measuring one or more biomarkers of liver function during administration of pirfenidone.

### Claim 54 (depends on 47, 48, 49, 50, 51, 52, 53)

The use according to any of claims 47-53, wherein said one or more biomarkers of liver function are alanine transaminase and aspartate transaminase.

### Claim 55

The method or use of any of the preceding claims, wherein the patient who would benefit from pirfenidone administration suffers from a condition selected from the group consisting of pulmonary fibrosis, idiopathic interstitial pneumonia, autoimmune lung diseases, benign prostate hypertrophy, coronary or myocardial infarction, atrial fibrillation, cerebral infarction, myocardiac fibrosis, musculoskeletal fibrosis, post-surgical adhesions, liver cirrhosis, renal fibrotic disease, fibrotic vascular disease, scleroderma, Hermansky-Pudlak syndrome, neurofibromatosis, Alzheimer's disease, diabetic retinopathy, skin lesions, and lymph node fibrosis associated with HIV.

### Claim 56

The method or use of any of the preceding claims wherein the patient who would benefit from pirfenidone administration suffers from a condition selected from the group consisting of chronic obstructive pulmonary disease (COPD), inflammatory pulmonary fibrosis (IPF), rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, sepsis, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, myofacial pain syndrome (MPS), Shigellosis, asthma, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, psoriasis, eczema, ulcerative colitis, glomerular nephritis, scleroderma, chronic thyroiditis, Grave's disease, Ormond's disease, autoimmune gastritis, myasthenia gravis, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, pancreatic fibrosis, chronic active hepatitis, acute and chronic renal disease, renal fibrosis, irritable bowel syndrome, pyresis, restenosis, cerebral malaria, stroke and ischemic injury, neural trauma, Huntington's disease, Parkinson's disease, acute and chronic pain, allergies, cardiac hypertrophy, chronic heart failure, acute coronary syndrome, cachexia, malaria, leprosy, leishmaniasis, Lyme disease, Reiter's syndrome, acute synoviitis, muscle degeneration, bursitis; tendonitis, tenosynoviitis, herniated, ruptured, or prolapsed intervertebral disk syndrome, osteopetrosis, thrombosis, silicosis, pulmonary sarcosis, bone resorption diseases, cancer, graft-versus-host reaction; and auto-immune diseases, AIDS, Herpes Zoster, Herpes Simplex I or II, influenza virus, Severe Acute Respiratory Syndrome (SARS), cytomegalovirus, and diabetes mellitus.
